The human cathepsin G (CG) gene is expressed only in promyelocytes and encodes a neutral serine protease that is packaged in the azurophil (primary) granules of myeloid cells. To define the cis-acting DNA elements that are responsible for promyelocyte-speciflc "targeting," we nijected a 6-kb transgene containing the entire human CG gene, including coding sequences contained in a 2.7-kb region, -2.5 kb of 5' flanking sequence, and "0.8 kb of 3' flanking sequence. Seven of seven "transient transgenic" murine embryos revealed human CG expression in the fetal livers at embryonic day 15. Stable trangenic founder lines were created with the same 6-kb fragment; four of five founder lines expressed human CG in the bone marrow. The level of human CG expression was relatively low per gene copy when compared with the endogenous murine CG gene, and expression was integration-site dependent; however, the level of gene expression correlated roughly with gene copy number. The human CG transgene and the endogenous murine CG gene were coordinately expressed in the bone marrow and the spleen. Immunohistochemical analysis of trngenic bone marrow revealed that the human CG protein was expressed exclusively in myeloid cells. Expression of human CG protein was highest in myeloid precursors and declined in mature myelold cells.
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These data suggest that the human CG gene was appropriately targeted and developmentally regulated, demonstrating that the cis-acting DNA sequences required for the early myeloid cell-specific expression of human CG are present in this small genomic fragment.
Several genes encoding neutral serine proteases are expressed exclusively in immature myeloid precursors at the promyelocyte/promonocyte stage of development (1) (2) (3) . Expression of these proteases is concomitant with the production of the azurophil (primary) granules in which these proteases are packaged (4) (5) (6) . Recently, neutrophil elastase and two highly related serine protease genes (proteinase 3 and azurocidin) have been shown to be clustered in a single genetic locus on human chromosome 19 (3) . These three genes are coordinately expressed during the promyelocyte stage of myeloid differentiation (1, 3) , suggesting that a unique regulatory mechanism controls expression ofall ofthe genes in this locus.
Like expression of the other azurophil granule-associated serine proteases, expression of cathepsin G (CG) is restricted to the promyelocyte/promonocyte stage of development (2, 7) . Interestingly, the CG gene and three other CG-like genes, encoding human granzyme B (CGL-1), human granzyme H (CGL-2), and mast cell chymase, form a cluster of hematopoietic serine protease genes located on chromosome 14 (8, 9) . Unlike the elastase-like genes on chromosome 19, the genes in this cluster are each expressed in distinct hematopoietic lineages (8) . The fact that each of the genes in this cluster is expressed in a distinct hematopoietic lineage suggests that separate mechanisms regulate the expression of each gene. Nevertheless, the restricted expression of CG in promyelocytes makes it an excellent model to study the factors that control myeloid development.
To identify the cis-acting regulatory sequences controlling the lineage-and development-specific expression of CG, we have examined the pattern of expression of a 6-kb human CG genomic fragment in transgenic mice. We (12) . Blots were probed with a unique random-primer-labeled 250-bp Xba I-HindIII fragment derived from the fifth exon and 3' flanking region of the human CG gene. These blots were reprobed with a unique 250-bp fiagment (generated by PCR amplification) derived from the 5' end of the murine granzyme A gene to provide a control for gene copy number. Comparison of densitometric scans of the signals corresponding to these two probes was used to estimate transgene copy number.
RNA Purification and S1 Nuclease Analysis. Total cellular RNA was prepared as described (11) . End-labeled probes were prepared and S1 nuclease protection assays were performed (2, 7) .
Immunohistochemistry and Immunofluorescence. Fivemicrometer-thick midsagittal cryostat sections of seven transgene-positive and two transgene-negative embryos were prepared for analysis. Slides of transgene-positive and -negative bone marrow cells were prepared by centrifugation for 5 min at 500 rpm using the Cytospin 3 cell-preparation system (Shandon, Pittsburgh kb of 3' flanking sequence; if the transcription initiation site is designated +1, the translation initiation site is located at +29 and the poly(A) addition site is at +2698 (8, 9) . We used a previously described approach for rapid analysis of the expression of this construct in transgenic mice, which will subsequently be referred to as the "transient transgenic" assay (14) ; it relies on the fact that the fetal liver is the major site of hematopoiesis in a developing mouse embryo at el.
Following microinjection of the human CG transgene, individual mouse embryos were harvested on e15 and frozen V.
Expression of the human CG transgene in the bone marrow of transgenic mice. Ten micrograms of total cellular RNA derived from each indicated source was hybridized simultaneously with probes specific for murine CG (mCG), murine P-microglobulin (mp2M), and human CG (hCG) mRNA. After hybridization, samples were treated with S1 nuclease as described (7) (Fig. 2) . RNA from the human promonocytic U937 cell line (lane 4) provided a positive control for human CG transcripts (8, 10) . Bone marrow RNA from transgene-negative littermates (lanes 5 and 11) showed the protected bands for endogenous murine CG and P2-microglobulin mRNAs; A%-microglobulin provided a control for integrity of the RNA samples. Expression of the human CG transgene was detected in four of the founder lines by this assay and was integration-site dependent. For most lines, expression of the human CG transgene was relatively low per gene copy with respect to the endogenous murine CG gene (Table 1) . However, despite the position effects of integration, expression of the human CG transgene did correlate roughly with copy number.
High-Level Expression of the Human CG Transgene Is Restricted to the Bone Marrow of Adult Mice. S1 nuclease protection assays using RNAs purified from the major organs of a mouse derived from founder line 12 showed high-level (Fig. 1C) . Transgene-positive bone marrow cells (founder line 12) showed intense cytoplasmic staining in cells with large, doughnut-shaped nuclei (Fig. 1D, arrows) The human CG transgene and the endogenous murine CG gene are expressed only in the bone marrow and spleen. An S1 nuclease protection analysis identical to that described in Fig. 2 is presented. Ten micrograms of total cellular RNA derived from the indicated organs of a transgenic F1 animal from founder line 12 was hybridized simultaneously with probes for murine CG (mCG), murine 82-microglobulin (mP32M), and human CG (hCG) mRNA. Note that hCG and mCG are primarily expressed in the bone marrow, although smaller amounts of both mRNAs are present in the spleen (lane 10). mouse antibody, 7/4, that detects a murine myeloid-specific protein (14) . The anti-human CG antiserum did not detect any cell type in transgene-negative bone marrow (Fig. 1E) . However, distinct cells (green in appearance) in transgenepositive bone marrow from founder line 17 were detected by the anti-human CG antiserum (Fig. 1F) . The 7/4 antibody detected the same cells (red in appearance, Fig. 1G ). The colocalization of human CG protein with the neutrophil marker recognized by 7/4 produced a yellow signal in these cells upon dual exposure (Fig. 1H) . Essentially all of the cells detected by the anti-human CG antiserum and the 7/4 antibody had a myeloid nuclear morphology. However, the larger, more immature myeloid precursors (arrows) appeared more green than yellow (Fig. 1H) Although the human CG transgene contains myeloid targeting sequences, its expression was integration-site dependent and relatively low compared to the endogenous murine CG gene. The levels of transgene expression appeared to correlate roughly with copy number, but copy-number dependence was difficult to interpret due to the effects of transgene integration. Interestingly, the 5' flanking region from another serine protease gene in the cluster on chromosome 14, encoding granzyme B, can appropriately target the expression of a heterologous gene to activated cytotoxic T cells; however, this transgene is also strongly influenced by position effects of integration (10) . Therefore, it is likely that the 6-kb human CG genomic fragment and the 5' flanking sequence ofthe granzyme B gene lack regulatory information (e.g., locus control) that insulates each gene from the effects of surrounding chromatin (15, 16) . A locus-control-like element may exist within or near the serine protease gene cluster that interacts with tissue-specific elements near each gene to permit high-level, lineage-specific expression. Alternatively, each gene within the cluster may have its own regulatory sequences that shield it from the effects of surrounding chromatin (17) .
CG expression is normally restricted to the promyelocyte stage of myeloid development (2, 7) . During this stage, CG protein is packaged into azurophil granules, which are distributed to the postmitotic, late-stage daughter cells as myeloid differentiation proceeds (4-6). Our immunohistochem-ical and immunofluorescence data demonstrate that expression of human CG protein in the bone marrow isolated from transgenic mice was most abundant in cells having an early myeloid morphology and that expression declined in more differentiated cells. This pattern suggests that the human CG transgene was expressed only at an early stage of myelopoiesis (e.g., promyelocytes). The weaker intensity of staining in the more mature cells suggests that expression of the transgene was appropriately down-regulated and that these cells contained protein that was produced at an earlier stage of development. It is unlikely that this phenomenon was due to protein degradation, since human CG protein was also detected in peripheral blood leukocytes isolated from these lines of transgenic mice (data not shown). These data suggest that the 6-kb fragment contains the signals for promyelocyte targeting and for the down-regulation of the CG gene with terminal myeloid differentiation.
Genetic programs controlling the expression of promyelocyte-specific genes and the factors involved in this program are not well understood. Cis-acting DNA elements important for the regulation of the neutrophil elastase gene (18) , the myeloperoxidase gene (19) (20) (21) , and the promyelocytespecific mim-1 gene (22) have been identified; however, the roles of these cis-acting elements for promyelocyte-specific targeting in transgenic animals have not been defined. Some information is available about transcription factors that bind to regulatory elements within or near these genes. For example, (i) an upstream element of the neutrophil elastase gene appears to be recognized by Ets family members (18) , (ii) a regulatory element upstream from the myeloperoxidase promoter is recognized by the partially characterized MyNF-1 factor (21), and (iii) the mim-1 5' flanking region contains binding sites for Myb, Ets, and C/EBP transcription factors (22) (23) (24) . Although the 5' flanking regions for human and mouse CG genes contain several conserved elements (7, 10) , the functional significance of these elements, and the proteins that bind them, have not been characterized in detail.
Based on the information obtained in this study, we suggest that transient transgenic analysis will be useful for defining the cis-acting DNA elements required for myeloid-specific expression. Since this assay does not require the generation of founder lines, it can be more rapidly performed than standard transgenic studies; when coupled with colocalization studies, it can provide detailed information about the specificity of targeting.
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